Document is current

Any future updates will be listed below

Risk of nephrogenic systemic fibrosis (NSF) in oncology patients receiving gadoxetic acid and updated risk of estimate of NSF in patients receiving gadoxetic acid with moderate and severe renal impairment

Crossref DOI link: https://doi.org/10.1007/s00261-021-03367-3

Published Online: 2022-01-07

Published Print: 2022-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark